Hakan Nacak1, Merel van Diepen1, Abdul R Qureshi2, Juan J Carrero2, Theo Stijnen3, Friedo W Dekker1, Marie Evans2. 1. The Department of Clinical Epidemiology, Leiden University Medical Center, Leiden, The Netherlands. 2. Renal Medicine, CLINTEC, Karolinska Institutet, Stockholm, Sweden. 3. The Department of Medical Statistics and Bioinformatics, Leiden University Medical Center, Leiden, The Netherlands.
Abstract
BACKGROUND: Although many studies have suggested an association between higher uric acid (UA) and both development of chronic kidney disease (CKD) and faster decline in renal function in Stage I and II CKD, it is not clear whether this effect is consistent throughout higher CKD stages. The aim of this study was to investigate the association between baseline UA and renal outcomes in patients with established CKD (Stages III-V). METHODS: We analysed data in the Swedish Renal Registry-Chronic Kidney Disease (SRR-CKD), which is a nationwide registry of referred CKD patients. Patients with a visit between January 1(st), 2005 and December 31(st), 2011 were followed until initiation of renal replacement therapy (RRT), death, referral to primary care or end of follow-up. Decline in renal function was assessed with a linear mixed model using all estimated glomerular filtration rate (eGFR) assessments recorded during median 28 months of follow-up, adjusting for important confounders such as demographic factors, primary renal disease, age, sex, relevant medication, diet, blood pressure and body mass index. RESULTS: There were 2466 patients with a baseline UA measurement {mean [standard deviation (SD)] of 7.81 [1.98] mg/dL}. The mean decline in renal function was -1.48 (95% CI -1.65; -1.31) mL/min/1.73 m(2) per year. The overall adjusted change in decline in renal function per unit increase in baseline UA was 0.08 (95% CI -0.01; 0.17) mL/min/1.73 m(2) per year indicating no association between higher UA levels and decline in renal function. In Stage III, IV and V CKD patients, the mean decline in renal function was -1.52 (95% CI -1.96; -1.08), -1.52 (95% CI -1.72; -1.32) and -1.19 (95% CI -1.75; -0.64) mL/min/1.73 m(2) per year, respectively. The adjusted change in the decline in renal function per unit increase in baseline UA was -0.09 (95% CI -0.30; 0.13) in Stage III CKD, 0.16 (95% CI 0.04; 0.28) in Stage IV CKD and 0.18 (95% CI -0.09; 0.45) in Stage V CKD. The overall adjusted hazard ratio for start of RRT was 0.97 (95% CI 0.93-1.02). For Stage III, IV and V CKD, it was 0.99 (95% CI 0.73-1.34), 0.97 (95% CI 0.91-1.03) and 0.99 (95% CI 0.91-1.07), respectively. CONCLUSION: UA is not associated with the rate of decline in renal function or time to start of RRT in Stage III, IV and/or V CKD patients.
BACKGROUND: Although many studies have suggested an association between higher uric acid (UA) and both development of chronic kidney disease (CKD) and faster decline in renal function in Stage I and II CKD, it is not clear whether this effect is consistent throughout higher CKD stages. The aim of this study was to investigate the association between baseline UA and renal outcomes in patients with established CKD (Stages III-V). METHODS: We analysed data in the Swedish Renal Registry-Chronic Kidney Disease (SRR-CKD), which is a nationwide registry of referred CKD patients. Patients with a visit between January 1(st), 2005 and December 31(st), 2011 were followed until initiation of renal replacement therapy (RRT), death, referral to primary care or end of follow-up. Decline in renal function was assessed with a linear mixed model using all estimated glomerular filtration rate (eGFR) assessments recorded during median 28 months of follow-up, adjusting for important confounders such as demographic factors, primary renal disease, age, sex, relevant medication, diet, blood pressure and body mass index. RESULTS: There were 2466 patients with a baseline UA measurement {mean [standard deviation (SD)] of 7.81 [1.98] mg/dL}. The mean decline in renal function was -1.48 (95% CI -1.65; -1.31) mL/min/1.73 m(2) per year. The overall adjusted change in decline in renal function per unit increase in baseline UA was 0.08 (95% CI -0.01; 0.17) mL/min/1.73 m(2) per year indicating no association between higher UA levels and decline in renal function. In Stage III, IV and V CKD patients, the mean decline in renal function was -1.52 (95% CI -1.96; -1.08), -1.52 (95% CI -1.72; -1.32) and -1.19 (95% CI -1.75; -0.64) mL/min/1.73 m(2) per year, respectively. The adjusted change in the decline in renal function per unit increase in baseline UA was -0.09 (95% CI -0.30; 0.13) in Stage III CKD, 0.16 (95% CI 0.04; 0.28) in Stage IV CKD and 0.18 (95% CI -0.09; 0.45) in Stage V CKD. The overall adjusted hazard ratio for start of RRT was 0.97 (95% CI 0.93-1.02). For Stage III, IV and V CKD, it was 0.99 (95% CI 0.73-1.34), 0.97 (95% CI 0.91-1.03) and 0.99 (95% CI 0.91-1.07), respectively. CONCLUSION:UA is not associated with the rate of decline in renal function or time to start of RRT in Stage III, IV and/or V CKD patients.
Authors: Laura G Sánchez-Lozada; Edilia Tapia; José Santamaría; Carmen Avila-Casado; Virgilia Soto; Tomás Nepomuceno; Bernardo Rodríguez-Iturbe; Richard J Johnson; Jaime Herrera-Acosta Journal: Kidney Int Date: 2005-01 Impact factor: 10.612
Authors: Won Jin Kim; Sang Soo Kim; Min Jung Bae; Yang Seon Yi; Yun Kyung Jeon; Bo Hyun Kim; Sang Heon Song; In Joo Kim; Yong Ki Kim Journal: J Diabetes Complications Date: 2013-11-20 Impact factor: 2.852
Authors: V Saroja Voruganti; Nora Franceschini; Karin Haack; Sandra Laston; Jean W MacCluer; Jason G Umans; Anthony G Comuzzie; Kari E North; Shelley A Cole Journal: Eur J Hum Genet Date: 2013-12-04 Impact factor: 4.246
Authors: Josef Fritz; Wolfgang Brozek; Hans Concin; Gabriele Nagel; Julia Kerschbaum; Karl Lhotta; Hanno Ulmer; Emanuel Zitt Journal: J Am Soc Nephrol Date: 2022-05-02 Impact factor: 14.978
Authors: Lennart Tonneijck; Marcel H A Muskiet; Mark M Smits; Petter Bjornstad; Mark H H Kramer; Michaela Diamant; Ewout J Hoorn; Jaap A Joles; Daniël H van Raalte Journal: Diabetes Obes Metab Date: 2018-02-20 Impact factor: 6.577
Authors: Joseph C Longenecker; Sana Waheed; Ghassan Bandak; Christine A Murakami; Blaithin A McMahon; Allan C Gelber; Mohamed G Atta Journal: BMC Nephrol Date: 2017-03-27 Impact factor: 2.388
Authors: Cynthia J Janmaat; Merel van Diepen; Cheyenne Ce van Hagen; Joris I Rotmans; Friedo W Dekker; Olaf M Dekkers Journal: Clin Epidemiol Date: 2018-05-25 Impact factor: 4.790